Welcome to our dedicated page for CARDINAL HEALTH SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Michelle D. Greene, Chief Information Officer of Cardinal Health, Inc. (CAH), filed a Form 4 reporting a securities transaction dated 08/12/2025. The filing lists transactions in common shares tied to performance share units, shows a reported quantity of 16,362 (marked with an "A") and another listed amount of 34,968 (marked with a "D"); the row shows a price of $0. The explanatory note states these are performance share units that will settle on August 15, 2025.
The form was signed by James E. Barnett, Attorney-in-fact on 08/12/2025. The filing identifies Greene's title and gives a reporting address in Dublin, Ohio. The document does not provide total outstanding shares or percent ownership, so materiality relative to the company-wide share count cannot be determined from this filing alone.
Deborah Weitzman, an officer listed as "CEO, PSS Segment" at Cardinal Health (CAH), was recorded as acquiring 39,100 performance share units on 08/12/2025 that are scheduled to settle on August 15, 2025.
The award is reported at a $0 price and is described as performance share units that will settle to common shares on the stated settlement date. After the reported acquisition, Ms. Weitzman’s beneficial ownership is shown as 88,229 common shares held directly. The filing shows this transaction as an acquisition (code A) and Table II reports no derivative securities.
Form 4 disclosure from Cardinal Health, Inc. (CAH) reports that Snow Ola M, the companys Chief Human Resources Officer, filed a change in beneficial ownership on 08/12/2025. The filing documents transactions in common shares tied to performance-based awards and is marked as a filing by one reporting person.
The tabular section lists the numeric entries 31,813 and 55,351 and shows a price of $0. The filing explicitly states these figures reflect performance share units that will settle on August 15, 2025. The form is signed by /s/ James E. Barnett, Attorney-in-fact dated 08/12/2025.
Cardinal Health insider transaction summary: Mary C. Scherer, listed as Chief Accounting Officer and reporting person for Cardinal Health, reported an acquisition of 3,029 common shares recorded as performance share units tied to the issuer. The transaction date is listed as 08/12/2025 and the filing states these performance share units will settle on August 15, 2025. Following the reported transaction the filing shows 11,691 common shares beneficially owned by the reporting person. The entry lists a $0 price, consistent with compensation-settled awards. This filing records a routine equity award rather than an open-market purchase or sale.
Jessica L. Mayer, Chief Legal/Compliance Officer of Cardinal Health (CAH), reported an acquisition of equity tied to performance awards. The Form 4 shows a transaction dated 08/12/2025 in which 49,994 common-share equivalents were recorded as acquired; the filing explains these are performance share units that will settle on 08/15/2025. The reported price is $0, consistent with a compensatory grant rather than a market purchase. After the reported transaction, Ms. Mayer's beneficial ownership is listed as 105,104 common shares.
This disclosure documents an executive equity grant converting to common shares on settlement and updates insider holdings for regulatory transparency. Table II contains no derivative transactions; the entry is limited to the performance-share settlement described in the explanation.
Stephen M. Mason, an officer of Cardinal Health, Inc. (CAH), reported a non-cash acquisition on 08/12/2025. The filing shows 54,537 performance share units acquired that, per the explanatory note, will settle into common shares on August 15, 2025 at an effective price of $0. After this award, the report lists 89,514 shares beneficially owned following the transaction. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, James E. Barnett, on 08/12/2025. The filing identifies the reporting person as an officer with title shown as CEO, GMPD Segment.
Jason M. Hollar, identified as Chief Executive Officer, filed a Form 4 for Cardinal Health, Inc. (CAH) reporting a transaction dated 08/12/2025. The filing shows an acquisition of 245,420 common shares recorded as performance share units that the filer states will settle on August 15, 2025. The reported price is $0 and the filing lists 437,235 shares beneficially owned following the reported transaction. The form is signed by James E. Barnett, Attorney-in-fact on 08/12/2025.
Cardinal Health Chief Financial Officer Aaron E. Alt reported a change in beneficial ownership on 08/12/2025. The Form 4 shows an acquisition of 67,448 common shares through performance share units that are stated to settle on August 15, 2025, with a reported transaction price of $0 (reflecting award settlement). Following the reported transaction, the filing lists total beneficial ownership of 102,396 shares. The filing was executed by an attorney-in-fact and contains an explanatory remark that the shares reflect performance share units.
Cardinal Health filed a Form S-3 shelf prospectus dated August 12, 2025 that permits the company to offer, from time to time, Class A common shares, preferred shares, unsecured debt securities, units or any combination of these securities; prospectus supplements will specify terms for each offering. The company is a well-known seasoned issuer and its common shares trade on the NYSE under the symbol CAH.
The Articles authorize up to 750 million common shares; as of June 30, 2025 approximately 271 million common shares were issued and about 32 million were held in treasury. The Articles also authorize 5 million Class B common shares (none outstanding) and 500,000 preferred non-voting shares (none outstanding).
The prospectus incorporates Cardinal Health’s Annual Report for the fiscal year ended June 30, 2025 and enumerates material risks including opioid-related litigation and a U.S. DOJ review of anti-diversion practices, the Company’s Corporate Integrity Agreement, EtO sterilization regulatory and litigation risks, high sales concentration with CVS Health, supply chain and tariff uncertainties, and commodity cost pressures. Net proceeds are intended for general corporate purposes.
Cardinal Health reported consolidated revenue of $222.6 billion for fiscal 2025, down 2% from the prior year largely because key Pharma distribution contracts with OptumRx expired (OptumRx accounted for 17% of consolidated revenue in fiscal 2024). Despite lower revenue, GAAP operating earnings rose 83% to $2.3 billion and GAAP diluted EPS increased 87% to $6.45, while non-GAAP operating earnings rose 15% to $2.8 billion and non-GAAP diluted EPS was $8.24, reflecting stronger branded and specialty pharmaceutical contributions and results from newly acquired MSO and at-home businesses.
The company deployed $5.3 billion for acquisitions in fiscal 2025, completed major transactions including a 73% interest in GI Alliance (~$2.8 billion), ADS ($1.1 billion), and ION ($1.1 billion), and recognized higher acquisition-related amortization and costs. Cash and equivalents fell to $3.9 billion, long-term obligations were $8.5 billion, and an opioid litigation accrual totaled $4.9 billion, while interest expense increased to $215 million due to new debt financing.